N/A - N/A Pick - Aiplexity

Waking up in the middle of The Alps, it’s just something to be lived at least once. Believe me you won’t forget it

Research brief

Sep 29, 2026 Afternoon

04:20 PM UTC

N/A N/A N/A

Final allocation: Keep cash (N/A)

After the stock-selection N/A, a separate review compared S&P 500 exposure (VOO; SPY is an equivalent market proxy) with Robinhood Gold cash over 28 days. Gold cash APY: 3.6%, checked 2026-09-29T17:34:45.222852+00:00; matched cash return: 0.2717%. Current base APY held constant; existing Gold subscription; pre-tax eligible settled cash, no margin debit or promotional boost.

Estimated net index return: +0.4000%; forecast uncertainty: 0.6000 percentage points; conservative excess over cash: -0.4717%.

Keep eligible settled cash in the existing Robinhood Gold cash program, pre-tax, with the existing Gold fee treated as sunk. The official 3.6% base APY snapshot was checked at 2026-09-29T17:34:45.222852+00:00; assuming that rate remains constant, with no margin debit or promotional boost, 100*((1+3.6/100)^(28/365)-1) = +0.271678% over exactly 28 calendar days. The APY can change. Robinhood cash rate. VOO's analyst net buy-and-hold forecast is +0.40%, but -0.20% after a positive 0.60-point uncertainty deduction, short of cash by 0.471678 point; the actual stop/profit policy's conservative executed return has not been shown to beat cash either. This is not a bearish inference from stock N/A: the complete 20-name stock audit remains intact, certified complete, with no positive uncertainty-adjusted actionable candidate after recovery. Separately, the runtime states existing public index exposure blocks another public VOO lot. Its ticker and size are not identified in the supplied 14-position list, so none is invented; the list already has substantial technology/AI-infrastructure and industrial names, while VOO itself held 37.87% information technology as of August 31, reinforcing the concentration cost of another index lot. Vanguard VOO fund page. SPY is a matched-horizon market proxy, not an extra VOO-versus-SPY eligibility hurdle; the comparison that decides this fallback is VOO versus Gold cash. No order is placed.

Decision frozen at 2026-09-29 13:34:45 ET for the 28 calendar days through 2026-10-27. This is a fresh, explicitly judgmental VOO buy-and-hold estimate, not the saved stock audit's earlier SPY forecast, a provider forecast, or an annual historical return scaled to 28 days. The last completed pre-review VOO five-minute bar ended 13:30 ET at $701.41; the subsequently returned 13:35 quote is after the decision timestamp and is not an entry assumption. Yahoo Finance VOO. Analyst price-return assumption: +0.50% over exactly 28 days, reflecting positive but already substantially priced earnings momentum, with no assumed multiple expansion. LSEG's September 25 scorecard reports Q3 2026 S&P 500 earnings growth estimated at 30.2% year over year and a 20.2x forward P/E as of September 24; these support upside but do not determine a 28-day return. LSEG earnings scorecard. The strongest contrary bullish evidence is FactSet's September 28 bottom-up 12-month index target implying 20.4% upside, but that is neither a 28-day prediction nor a basis for prorating it. FactSet analyst targets. Against it, the Fed raised its funds target to 3.75%-4.00% on September 16, and the latest pre-review posted 10-year Treasury yield was 5.24% on September 28, versus 5.17% on September 25; higher discount rates make a 20.2x forward multiple vulnerable to near-term repricing. Federal Reserve statement; Treasury yield curve. VOO's September distribution went ex-dividend September 28, before this entry, and was payable September 30; Vanguard lists quarterly distributions, so assume no cash distribution earned by a September 29 buyer through October 27. Fund dividends and expense drag already flow through market price/NAV between distributions; do not add a prorated yield or subtract the 0.03% annual fund expense a second time. Vanguard VOO fund page. Allow 0.10% round-trip spread/slippage/friction, above the fund's reported 0.004% 30-day median spread, for a +0.40% net buy-and-hold forecast. The separate +0.60 percentage-point forecast-uncertainty deduction is an uncalibrated analyst allowance for the short window's earnings-realization timing and rate/valuation sensitivity, not ATR, VIX, a one-sigma move, or a second charge for a modeled downside outcome. Thus conservative net return is -0.20%, below cash. Sensitivity: with +0.50% price return and 0.10% friction, uncertainty would need to be below 0.1283 point to beat cash; with 0.60-point uncertainty, price return would need to exceed 0.9717%. An illustrative +1.20% price return would clear the buy-and-hold test, while -1.00% would not; these are sensitivities, not probability-calibrated forecasts. The policy-executed VOO hurdle would still have to clear cash separately before any purchase, and no new VOO trade is authorized here. Surf Google search required human intervention, was not retried, and independent native search plus directly accessible primary sources supplied the evidence; this access issue is not market evidence.

The following stock-selection report is retained as the prior research record.

Summary

Recommendation: no new single-stock purchase on September 29, 2026. This is the decider's audited, non-crash N/A, not a directional call to sell the market or an automatic decision between index exposure and cash. The 20-row audit above contains eight fully specified actionable scenarios and twelve hard rejections; one additional candidate-generation round was completed. The selection rule requires positive 28-day absolute net return after forecast uncertainty, not merely positive expected return before uncertainty or SPY outperformance.
Closest stock cases still miss. At the 13:16 ET quote refresh, IDT was $76.885; the decider's net policy-return estimate was +1.6256%, but its 2.10-percentage-point uncertainty deduction left −0.4744%. ZYME was $27.22; its +1.9972% policy-return estimate became −0.4028% after 2.40 points of uncertainty. Quote observations and event-path diagnostics are supported by the dated price series. finance.yahoofinance.yahoo
Benchmark comparison is not the veto. The decider estimated +0.40% net SPY buy-and-hold return for the same September 29–October 27, 28-calendar-day interval: assumed +0.50% price drift, zero in-window distribution and −0.10% trading friction. State Street's cited distribution dates are September 18 and December 18; the price drift is an analyst assumption, not a provider forecast. finance.yahoossga
Confidence: Medium in the process decision, not in any positive stock forecast. The complete structured audit and a coherent adverse-stress check support withholding a stock recommendation, but the policy-exit probabilities are uncalibrated analyst judgments, and several audit rows have weaker source attribution than the leading cases. This is not a confidence gate.

Why Now

The September 29 intraday market snapshot was selective rather than a confirmed broad crash: SPY was $762.48 and down approximately 0.40%, and the screen showed 127 advancers among 501 S&P constituents. The latest posted 10-year Treasury yield was 5.24% on September 28, not a live September 29 yield; VIX was 16.26 at 12:09 ET. These are market observations, not a forecast or automatic reasons to reject stocks. finance.yahoofinance.yahoohome.treasuryfinance.yahoo

The most time-sensitive operating news was real, but price acceptance and cash transmission were mixed. IDT's September 28 fiscal-quarter release reported revenue of $339.0 million (+7% year over year), gross margin of 39.8% (+360 basis points), and operating income of $33.2 million (+52%); its full-year deposit-adjusted operating cash flow nevertheless fell to $60.9 million from $107.8 million. idt.net Zymeworks closed the Theravance acquisition on September 28 and updated 2026 guidance to $278 million–$292 million revenue and $114 million–$128 million EBITDA, but 75% of the YUPELRI profit share is pledged toward a $350 million note. globenewswire The decider treated those facts as both catalysts and limitations rather than assuming either announcement creates cash within 28 days.

One recovery round followed the failure of the initial finalists to clear the absolute-return gate. It combined a broad screen and independent idea searches, then evaluated new candidates including ZYME and IOVA; the challenged search service was not retried. The audit counts 20 distinct reviewed symbols, not just the finalists displayed in prose. Its decision is a completed stock-selection N/A; a separate allocation review must still compare index exposure with interest-bearing cash.

Business And Market Context

The near-misses span unrelated businesses, which matters more than a generic risk-off label. IDT's communications and payments businesses produced the reported quarterly margin and operating-income improvement, while weaker annual deposit-adjusted cash conversion limits confidence in extrapolating the quarter. idt.net ZYME's acquired YUPELRI economics support its updated guidance, but a large pledged profit-share claim limits immediate common-equity cash capture. globenewswire Coherent's PhotonLink optical platform and capacity expansion lacked quantified booked orders or near-term revenue in the supplied research; AAR's MRO acquisition would not close until fiscal Q3 ending February 2027 and involved approximately $2.1 billion of new debt plus $780 million of stock issuance. ir.coherentaarcorpaarcorp

The current portfolio already has active public positions in ANET, BE, CEG, CTAS, DELL, DG, DOCU, GEV, GME, GNRC, HPE, INSM, SMCI and SOFI, so those symbols are unavailable for a second public lot under the supplied one-lot rule. None of the 20 audited names duplicates that list. Technology is already 12.45% of total portfolio value and industrials 10.15%, with 67.42% unallocated cash; the existing AI-infrastructure and industrial exposure adds a concentration penalty to marginal COHR/MRVL/AIR ideas, not an automatic exclusion. These portfolio figures are supplied runtime inputs rather than independently verified brokerage balances. A prior closed holding would likewise be a penalty, not a veto.

The 28-day SPY benchmark is the decider's net estimate, not SPY's trailing return: +0.50% assumed price change, +0.00% expected distributions inside the holding window, and −0.10% friction. The cited SPY quote and distribution timetable support the starting point and dividend assumption, while the price-drift forecast remains subjective. finance.yahoossga An early stock exit is modeled as cash through October 27; SPY is modeled as held through that same date.

Factor Stack

Factor	Evidence and interpretation
Catalyst and freshness	IDT's September 28 operating-income acceleration and ZYME's September 28 completed deal/guidance update are verified positives. idt.netglobenewswire Decider inference: neither provides enough supported incremental 28-day policy-exit edge at refreshed prices.
Growth and cash quality	IDT's +52% quarterly operating income contrasts with a FY26 deposit-adjusted operating-cash decline; ZYME's profit-share debt claim reduces direct cash capture. idt.netglobenewswire
Valuation and balance sheet	IDT reported $271.9 million of unrestricted cash and liquid investments and no debt. idt.net Coherent's cited quote profile reported trailing P/E 71.4 and beta 2.10; these inform—not numerically determine—the decider's 3.00-point uncertainty deduction. finance.yaho
Momentum and entry geometry	IDT's $76.885 refresh approached $77.28 first resistance; ZYME at $27.22 was below its $27.38 session VWAP. The $77.28 and $27.38 levels are path diagnostics, not four-week T1 targets. finance.yahoofinance.yahoo
Sentiment and revisions	Social discussion was used as an idea lead, not issuer verification. No matched 28-day, policy-exit reference class or substantiated near-term analyst revision series was supplied; the probabilities below are therefore explicitly uncalibrated decider assumptions.
Portfolio fit	No audited name is an active-symbol duplicate, but technology and industrial crowding make their marginal additions less attractive under otherwise equal forecasts. This is an analyst allocation judgment from the supplied portfolio, not a hard gate.

Investment Thesis

The thesis is to withhold a new single-stock lot because the supported scenario set has no positive uncertainty-adjusted absolute return. For each actionable candidate, the decider modeled mutually exclusive full-position profit-barrier, conditional stop-exit and time-exit outcomes, then subtracted estimated execution friction. The following are decider estimates and arithmetic, not source-reported returns or calibrated probabilities. All rows use 28 calendar days, the same execution policy, and the +0.40% net SPY estimate. Full numerical inputs and evidence bases remain in the exact 20-row frontmatter audit.

Actionable candidate	Net policy EV	EV minus uncertainty	Net SPY excess	Adjusted SPY excess	Decision-critical condition
ZYME	+1.9972%	−0.4028%	+1.5972 pp	−0.8028 pp	Best modeled alternate; debt-encumbered profit share and below-VWAP tape. globenewswirefinance.yahoo
IDT	+1.6256%	−0.4744%	+1.2256 pp	−0.8744 pp	Fresh earnings, but cash conversion and price drift narrow the barrier-to-stop path. idt.netfinance.yahoo
BRX	+0.3429%	−1.4571%	−0.0571 pp	−1.8571 pp	Slate transaction is expected to close in Q1 2027, outside this horizon. investors.br
COHR	+1.1797%	−1.8203%	+0.7797 pp	−2.2203 pp	Optical launch lacks quantified near-term orders. ir.coherent
ORCL	+1.0481%	−1.9519%	+0.6481 pp	−2.3519 pp	Q1 free cash flow was −$5 billion, and the post-earnings tape lagged XLK. investor.orafinance.yaho
AIR	+0.3173%	−2.1827%	−0.0827 pp	−2.5827 pp	Acquisition funding and heavy-volume selloff impair near-term acceptance. aarcorpfinance.yaho
IOVA	+0.9126%	−2.5874%	+0.5126 pp	−2.9874 pp	Raised FY26 guidance, but a roughly 39% session surge and clinical-presentation risk enlarge forecast error. sec.govfinance.yaho
MRVL	−0.4412%	−2.9412%	−0.8412 pp	−3.3412 pp	Optical demonstration lacks quantified new booked revenue. marvell

T1 is not the exit. At IDT's $76.885 entry, $77.28 is first resistance and $80.00 is the decider's 28-day T1; the actual full-position profit barrier is $82.492, or 1.8 × T1's 4.052% percentage gain = 7.293%, not $80 and not 1.8 × $80. The decider assumed a 35% profit-barrier exit, 30% stop exit and 35% time exit at a conditional +2.0%; it used a $74.30 authored stop, a $73.10 estimated actual stop exit and 0.15% friction. finance.yahoo At ZYME's $27.22 entry, $27.38 is first resistance, $29.50 is T1 and $31.324 is the 1.8-times-percentage-return barrier (+15.077%). Its assumed exit odds were 30%/35%/35%, time return +1.0%, authored stop $25.50, conditional stop exit $25.10 and friction 0.15%. finance.yahoo These barriers require clearing the nearby resistance and continuing farther; an intraday touch of T1 is not the modeled profit exit.

The quote refresh matters. IDT at $76.37 at 12:45 ET had a decider-estimated +0.1596% margin after uncertainty; by 13:16 ET it had moved to $76.885, shrinking remaining T1 travel while increasing distance to the conditional stop exit. With odds held fixed to isolate price drift, its net EV became +1.6256% and its adjusted return −0.4744%. finance.yahoo That is a forecast-geometry deterioration, not a claim that $77.28 is the terminal target.

The adverse-scenario checks did not rescue either case. For IDT the decider shifted 10 probability points from profit to stop and lowered the conditional stop fill $0.50 to $72.60, motivated by weaker cash conversion and nearby resistance; stressed EV was +0.1439%, stressed SPY excess −0.2561 point, and the minimum uncertainty consistency value 1.4817 points, below its declared 2.10 points. idt.netfinance.yahoo For ZYME it shifted six points from profit to stop, lowered the stop fill $0.30 to $24.80 and set conditional time return to zero, motivated by below-VWAP tape and pledged profit share; stressed EV was −0.1766%, excess −0.5766 point and minimum consistency value 2.1738 points, below its declared 2.40 points. finance.yahooglobenewswire SPY remained +0.40% in both issuer-specific stresses. The decider's scenario check returned declared_uncertainty_covers_stress: true for both. This is an arithmetic sensitivity test, neither empirical calibration of the assumed odds nor proof that the base return forecast is true. ATR, beta and VIX describe return dispersion, not an automatic deduction from expected return; downside branches and the uncertainty deduction should not count the same risk twice.

Risks And Thesis Breakers

Execution and gap risk: The specified policy requires a trailing 60-minute average to remain below the authored stop for 120 minutes; a 15% hard-loss condition requires 10 minutes of confirmation. A stop threshold is therefore not an assured sale price. Gaps, the confirmation delay and market liquidity can make actual exits worse than the authored level or the estimated conditional stop_exit_price. The forecasts include at least 0.1% adverse slippage (0.15% friction for IDT/ZYME), but neither that allowance nor the 15% condition caps loss. Early exits are treated as cash for the rest of the 28-day comparison.
Catalyst-acceptance breakers: AKAM's September 25 post-announcement gap failed below its $113.84 event low and $107.64 event VWAP; SMMT's financing surge faded beneath its $16.795 event VWAP; NUE's $237.44 quote broke the $241.21 post-guidance support shelf. Each lacks the decider's currently required event-VWAP base or unbroken support/stop geometry, so the audit records mandatory_trigger_or_broken_support rather than assigning invented exit odds. finance.yahofinance.yahofinance.yaho
Fundamental and timing breakers: Additional IDT cash-conversion deterioration, ZYME's pledged-profit cash diversion, a further below-VWAP fade, or an IOVA clinical presentation that gaps through an executable stop would weaken the relevant long case. The first two are tied to reported cash/debt terms and observed tape; the future developments are conditional analyst risk scenarios, not events already known to have occurred. idt.netglobenewswirefinance.yahoofinance.yaho
Evidence limitations: The supplied audit contains concrete but not uniformly citation-backed rejection narratives. In particular, MTN and NIO rows lack a source citation for their company-specific factual assertions, and several recovery rows cite a broad screen rather than a document for every asserted missing input. Those rows are preserved verbatim as the decider's structured audit, not promoted here as independently verified facts. The decider did not supply a market_regime_evidence field; the frontmatter marks that absence rather than inventing a crash-regime finding. The N/A rests on the completed no-positive-candidate pathway, not a certified bear-market claim. Forecast probabilities and uncertainty deductions also lack a policy-matched historical reference class.
Information access: An earlier search service required human intervention and was not bypassed; the handoff reports independent search and issuer/regulator checks instead. Search obstruction is an access limitation, not market evidence. The decision could change with a genuinely new release, a verified support reclaim or a materially different same-session entry quote; it should not be reused as a standing four-week prohibition.

Investment Recommendation

Do not open a new single-stock position now. The decider's complete 20-candidate audit, one recovery round and eight negative uncertainty-adjusted actionable forecasts support no_positive_actionable_candidate_after_recovery. ZYME's −0.4028% adjusted absolute return is the least negative, only 0.0716 percentage point better than IDT's −0.4744%; neither clears the strict greater-than-zero absolute gate. Their unadjusted SPY excess estimates (+1.5972 and +1.2256 points) do not change that rule. SPY's +0.40% net estimate is a matched-horizon opportunity-cost comparison, not an instruction to buy SPY here; a separate allocation decision must compare index exposure with the verified cash alternative. This recommendation is not based on confidence, weak SPY excess alone, or an assumed exact stop fill.

For future reconsideration, require a fresh quote and a fully re-frozen 28-day scenario. IDT would need enough supported barrier probability or improved entry-to-stop geometry to overcome at least the documented 2.10-point uncertainty deduction; ZYME would need verified post-deal cash transmission and price acceptance sufficient to overcome its 2.40-point deduction. Broken-support names need the specified post-event base or unbroken next-session support, not merely a cheaper price. These are conditional watch criteria, not price targets, guaranteed outcomes or orders.